Idiopathic pulmonary fibrosis: TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis

Science Translational Medicine

Volumn 2, Issue 57, 2010, Pages

  Trujillo, Glenda ^a   Meneghin, Alessia ^a   Flaherty, Kevin R ^a   Sholl, Lynette M ^b   Myers, Jeffrey L ^a   Kazerooni, Ella A ^a   Gross, Barry H ^a   Oak, Sameer R ^a   Coelho, Ana Lucia ^a   Evanoff, Holly ^a   Day, Elizabeth ^c   Toews, Galen B ^a   Joshi, Amrita D ^a   Schaller, Matthew A ^a   Waters, Beatrice ^c   Jarai, Gabor ^c   Westwick, John ^c   Kunkel, Steven L ^a   Martinez, Fernando J ^a   Hogaboam, Cory M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Novartis Institutes of Biomedical Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9; BACTERIAL DNA; TLR9 PROTEIN, HUMAN; VIRUS DNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN; CELL STRAIN A549; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG BIOPSY; LUNG FIBROBLAST; MALE; MONOCYTE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SCID MOUSE; TISSUE LEVEL; AGED; CELL DIFFERENTIATION; CELL LINE; CPG ISLAND; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; CELL DIFFERENTIATION; CELL LINE; CPG ISLANDS; DISEASE PROGRESSION; DNA, BACTERIAL; DNA, VIRAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; TOLL-LIKE RECEPTOR 9;

EID: 78349285513     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001510     Document Type: Article

References (51)

1. T. A. Wynn, Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210 (2008).
2. G. J. Laurent, R. J. McAnulty, M. Hill, R. Chambers, Escape from the matrix: Multiple mechanisms for fibroblast activation in pulmonary fibrosis. Proc. Am. Thorac. Soc. 5, 311-315 (2008).
3. B. Mehrad, M. D. Burdick, D. A. Zisman, M. P. Keane, J. A. Belperio, R. M. Strieter, Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem. Biophys. Res. Commun. 353, 104-108 (2007).
4. Y. Ishida, A. Kimura, T. Kondo, T. Hayashi, M. Ueno, N. Takakura, K. Matsushima, N. Mukaida, Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration. Am. J. Pathol. 170, 843-854 (2007).
5. B. B. Moore, L. Murray, A. Das, C. A. Wilke, A. B. Herrygers, G. B. Toews, The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am. J. Respir. Cell Mol. Biol. 35, 175-181 (2006).
6. T. Kisseleva, H. Uchinami, N. Feirt, O. Quintana-Bustamante, J. C. Segovia, R. F. Schwabe, D. A. Brenner, Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J. Hepatol. 45, 429-438 (2006).
7. M. Iwano, D. Plieth, T. M. Danoff, C. Xue, H. Okada, E. G. Neilson, Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341-350 (2002).
8. K. K. Kim, M. C. Kugler, P. J. Wolters, L. Robillard, M. G. Galvez, A. N. Brumwell, D. Sheppard, H. A. Chapman, Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. U.S.A. 103, 13180-13185 (2006).
9. K. A. Rygiel, H. Robertson, H. L. Marshall, M. Pekalski, L. Zhao, T. A. Booth, D. E. Jones, A. D. Burt, J. A. Kirby, Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab. Invest. 88, 112-123 (2008).
10. M. Zeisberg, C. Yang, M. Martino, M. B. Duncan, F. Rieder, H. Tanjore, R. Kalluri, Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337-23347 (2007).
11. F. J. Martinez, S. Safrin, D. Weycker, K. M. Starko, W. Z. Bradford, T. E. King Jr., K. R. Flaherty, D. A. Schwartz, P. W. Noble, G. Raghu, K. K. Brown; IPF Study Group, The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med. 142, 963-967 (2005).
12. R. Hyzy, S. Huang, J. Myers, K. Flaherty, F. Martinez, Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132, 1652-1658 (2007).
13. M. Selman, G. Carrillo, A. Estrada, M. Mejia, C. Becerril, J. Cisneros, M. Gaxiola, R. Pérez-Padilla, C. Navarro, T. Richards, J. Dauber, T. E. King Jr., A. Pardo, N. Kaminski, Accelerated variant of idiopathic pulmonary fibrosis: Clinical behavior and gene expression pattern. PLoS One 2, e482 (2007).
14. K. Tsukamoto, H. Hayakawa, A. Sato, K. Chida, H. Nakamura, K. Miura, Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 55, 958-961 (2000).
15. J. P. Stewart, J. J. Egan, A. J. Ross, B. G. Kelly, S. S. Lok, P. S. Hasleton, A. A. Woodcock, The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 159, 1336-1341 (1999).
16. Y. W. Tang, J. E. Johnson, P. J. Browning, R. A. Cruz-Gervis, A. Davis, B. S. Graham, K. L. Brigham, J. A. Oates Jr., J. E. Loyd, A. A. Stecenko, Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Microbiol. 41, 2633-2640 (2003).
17. T. R. McMillan, B. B. Moore, J. B. Weinberg, K. M. Vannella, W. B. Fields, P. J. Christensen, L. F. van Dyk, G. B. Toews, Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am. J. Respir. Crit. Care Med. 177, 771-780 (2008).
18. S. Guggemoos, D. Hangel, S. Hamm, A. Heit, S. Bauer, H. Adler, TLR9 contributes to antiviral immunity during gammaherpesvirus infection. J. Immunol. 180, 438-443 (2008).
19. A. Meneghin, E. S. Choi, H. L. Evanoff, S. L. Kunkel, F. J. Martinez, K. R. Flaherty, G. B. Toews, C. M. Hogaboam, TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem. Cell Biol. 130, 979-992 (2008).
20. K. R. Flaherty, T. E. King Jr., G. Raghu, J. P. Lynch III, T. V. Colby, W. D. Travis, B. H. Gross, E. A. Kazerooni, G. B. Toews, Q. Long, S. Murray, V. N. Lama, S. E. Gay, F. J. Martinez, Idiopathic interstitial pneumonia: What is the effect of a multidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 170, 904-910 (2004).
21. H. R. Collard, B. B. Moore, K. R. Flaherty, K. K. Brown, R. J. Kaner, T. E. King Jr., J. A. Lasky, J. E. Loyd, I. Noth, M. A. Olman, G. Raghu, J. Roman, J. H. Ryu, D. A. Zisman, G. W. Hunninghake, T. V. Colby, J. J. Egan, D. M. Hansell, T. Johkoh, N. Kaminski, D. S. Kim, Y. Kondoh, D. A. Lynch, J. Müller-Quernheim, J. L. Myers, A G. Nicholson, M. Selman, G. B. Toews, A. U. Wells, F. J. Martinez; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators, Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 176, 636-643 (2007).
22. D. Pilling, C. D. Buckley, M. Salmon, R. H. Gomer, Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol. 171, 5537-5546 (2003).
23. D. D. Shao, R. Suresh, V. Vakil, R. H. Gomer, D. Pilling, Pivotal Advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J. Leukoc. Biol. 83, 1323-1333 (2008).
24. K. M. Hong, J. A. Belperio, M. P. Keane, M. D. Burdick, R. M. Strieter, Differentiation of human circulating fibrocytes as mediated by transforming growth factor-b and peroxisome proliferator-activated receptor g. J. Biol. Chem. 282, 22910-22920 (2007).
25. L. Yang, P. G. Scott, J. Giuffre, H. A. Shankowsky, A. Ghahary, E. E. Tredget, Peripheral blood fibrocytes from burn patients: Identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab. Invest. 82, 1183-1192 (2002).
26. M. Schnoor, P. Cullen, J. Lorkowski, K. Stolle, H. Robenek, D. Troyer, J. Rauterberg, S. Lorkowski, Production of type VI collagen by human macrophages: A new dimension in macrophage functional heterogeneity. J. Immunol. 180, 5707-5719 (2008).
27. R. Abe, S. C. Donnelly, T. Peng, R. Bucala, C. N. Metz, Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites. J. Immunol. 166, 7556-7562 (2001).
28. B. N. Gomperts, R. M. Strieter, Fibrocytes in lung disease. J. Leukoc. Biol. 82, 449-456 (2007).
29. C. Moreno, J. Merino, N. Ramírez, A. Echeverría, F. Pastor, A. Sánchez-Ibarrola, Lipopolysaccharide needs soluble CD14 to interact with TLR4 in human monocytes depleted of membrane CD14. Microbes Infect. 6, 990-995 (2004).
30. Ø. Sandanger, L. Ryan, J. Bohnhorst, A. C. Iversen, H. Husebye, Ø. Halaas, L. Landrø, P. Aukrust, S. S. Frøland, G. Elson, A. Visintin, O. Øktedalen, J. K. Damås, A. Sundan, D. Golenbock, T. Espevik, IL-10 enhances MD-2 and CD14 expression in monocytes and the proteins are increased and correlated in HIV-infected patients. J. Immunol. 182, 588-595 (2009).
31. J. K. Rho, Y. J. Choi, J. K. Lee, B. Y. Ryoo, I. I. Na, S. H. Yang, C. H. Kim, J. C. Lee, Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63, 219-226 (2009).
32. S. A. Illman, K. Lehti, J. Keski-Oja, J. Lohi, Epilysin (MMP-28) induces TGF-β mediated epithelial to mesenchymal transition in lung carcinoma cells. J. Cell Sci. 119, 3856-3865 (2006).
33. H. Kasai, J. T. Allen, R. M. Mason, T. Kamimura, Z. Zhang, TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res. 6, 56 (2005).
34. T. Ronni, S. Matikainen, T. Sareneva, K. Melén, J. Pirhonen, P. Keskinen, I. Julkunen, Regulation of IFN-α/β, MxA, 2′,5′-oligoadenylate synthetase, and HLA gene expression in influenza A-infected human lung epithelial cells. J. Immunol. 158, 2363-2374 (1997).
35. Y. Osawa, S. Iho, R. Takauji, H. Takatsuka, S. Yamamoto, T. Takahashi, S. Horiguchi, Y. Urasaki, T. Matsuki, S. Fujieda, Collaborative action of NF-κB and p38 MAPK is involved in CpG DNA-induced IFN-a and chemokine production in human plasmacytoid dendritic cells. J. Immunol. 177, 4841-4852 (2006).
36. E.M. Pierce, K. Carpenter, C. Jakubzick, S. L. Kunkel, K. R. Flaherty, F. J. Martinez, C.M. Hogaboam, Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am. J. Pathol. 170, 1152-1164 (2007).
37. A. Moeller, S. E.Gilpin, K. Ask, G. Cox, D. Cook, J. Gauldie, P. J. Margetts, L. Farkas, J. Dobranowski, C. Boylan, P. M. O'Byrne, R. M. Strieter, M. Kolb, Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179, 588-594 (2009).
38. C. Balmelli, M. P. Alves, E. Steiner, D. Zingg, N. Peduto, N. Ruggli, H. Gerber, K. McCullough, A. Summerfield, Responsiveness of fibrocytes to toll-like receptor danger signals. Immunobiology 212, 693-699 (2007).
39. D. Droemann, D. Albrecht, J. Gerdes, A. J. Ulmer, D. Branscheid, E. Vollmer, K. Dalhoff, P. Zabel, T. Goldmann, Human lung cancer cells express functionally active Toll-like receptor 9. Respir. Res. 6, 1 (2005).
40. M. Königshoff, N. Balsara, E. M. Pfaff, M. Kramer, I. Chrobak, W. Seeger, O. Eickelberg, Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 3, e2142 (2008).
41. K. K. Kim, Y. Wei, C. Szekeres, M. C. Kugler, P. J. Wolters, M. L. Hill, J. A. Frank, A. N. Brumwell, S. E. Wheeler, J. A. Kreidberg, H. A. Chapman, Epithelial cell α3β1 integrin links β-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J. Clin. Invest. 119, 213-224 (2009).
42. E. Gäbele, M. Mühlbauer, C. Dorn, T. S. Weiss, M. Froh, B. Schnabl, R. Wiest, J. Schölmerich, F. Obermeier, C. Hellerbrand, Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem. Biophys. Res. Commun. 376, 271-276 (2008).
43. H. J. Anders, V. Vielhauer, V. Eis, Y. Linde, M. Kretzler, G. Perez de Lema, F. Strutz, S. Bauer, M. Rutz, H. Wagner, H. J. Gröne, D. Schlöndorff, Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J. 18, 534-536 (2004).
44. J. M. Ilvesaro, M. A. Merrell, L. Li, S. Wakchoure, D. Graves, S. Brooks, E. Rahko, A. Jukkola-Vuorinen, K. S. Vuopala, K. W. Harris, K. S. Selander, Toll-like receptor 9 mediates CpG oligonucleotide- induced cellular invasion. Mol. Cancer Res. 6, 1534-1543 (2008).
45. J. M. Ilvesaro, M. A. Merrell, T. M. Swain, J. Davidson, M. Zayzafoon, K. W. Harris, K. S. Selander, Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67, 774-781 (2007).
46. M. A. Merrell, J. M. Ilvesaro, N. Lehtonen, T. Sorsa, B. Gehrs, E. Rosenthal, D. Chen, B. Shackley, K. W. Harris, K. S. Selander, Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol. Cancer Res. 4, 437-447 (2006).
47. E. A. Kazerooni, F. J. Martinez, A. Flint, D. A. Jamadar, B. H. Gross, D. L. Spizarny, P. N. Cascade, R. I. Whyte, J. P. Lynch III, G. Toews, Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: Correlation with pathologic scoring. AJR Am. J. Roentgenol. 169, 977-983 (1997).
48. K. R. Flaherty, A. C. Andrei, S. Murray, C. Fraley, T. V. Colby, W. D. Travis, V. Lama, E. A. Kazerooni, B. H. Gross, G. B. Toews, F. J. Martinez, Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minute-walk test. Am. J. Respir. Crit. Care Med. 174, 803-809 (2006).
49. U.S. National Institutes of Health, ClinicalTrials.gov, www.clinicaltrials.gov.
50. L. Ivanova, M. J. Butt, D. G. Matsell, Mesenchymal transition in kidney collecting duct epithelial cells. Am. J. Physiol. Renal Physiol. 294, F1238-F1248 (2008).
51. Acknowledgments: We thank the National Heart, Lung and Blood Institute-sponsored Lung Tissue Research Consortium and R. Kunkel for her expertise in the preparation of the final figures. Funding: This worked was supported, in part, by NIH funding via P50HL56402 (to C.M.H., K.R.F., and F.J.M.) and HL073728 (to C.M.H.). The authors also acknowledge the financial support of Novartis Institute of Biomedical Research and Novartis Pharmaceuticals UK Ltd. G.T. received funding from an NIH Institutional Training Grant (T32) for Pulmonary Research at the University of Michigan Medical School. Author contributions: G.T. and C.M.H. designed and analyzed all the experiments and data. G.T. performed all the experiments except for the TLR9 TaqMan assays, which were performed and analyzed by A.M. and S.R.O., the IPF fibroblast enzyme-linked immunosorbent assays (ELISAs), which were performed and analyzed by A.M., and the TLR9 immunohistochemistry, which was performed by A.L.C. F.J.M., K.R.F., L.M.S., J.L.M., E.A.K., B.H.G., G.B.T., and C.M.H. collected and interpreted the clinical data. H.E., A.D.J., and B.W. provided technical assistance. E.D., A.D.J., M.A.S., G.J., J.W., and S.L.K. contributed to the critical review of the study and the interpretation of the data. G.T., F.J.M., and C.M.H. wrote the paper. Competing interests: Novartis and the University of Michigan have filed a patent on the diagnostic use of TLR9 as a biomarker for fibrosis on which G.T., S.L.K., and C.M.H. are co-inventors. The other authors declare that they have no conflicts of interest.